70 CHAPTER 4 Table 1 | Summary table of preventive interventional trials in individuals at risk of developing rheumatoid arthritis (continued) Trial name Inclusion criteria Number of patients (treatment vs placebo) Intervention Time of follow-up Primary outcome Secondary outcome Results Reference PRAIRI study - Arthralgia - ACPA and RF positivity - CRP>0.6 mg/L - Subclinical synovitis (detected either by MRI with gadolinium or ultrasound) - Absence of inflammatory arthritis 81 patients (41 treatment vs 40 placebo) 100 mg methylprednisolone + single gift of 1000 mg rituximab at baseline - 12 months - 18 months - 5 years - Time to development of clinical arthritis - Circulating autoantibody levels - Peripheral T and B cell numbers and subpopulations - Decreased baseline risk of RA at 12 months (55% in treatment group) and 18 months (53%) - 12 month delay of RA development after rituximab treatment - Significant depletion of B cells - Significant decrease in IgA-RF, IgM-RF and total IgM after treatment [64]
RkJQdWJsaXNoZXIy MTk4NDMw